CT-721, a Potent BCR-Abl Inhibitor, Exhibits Excellent in Vitro and in Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Journal of Cancer - Australia
doi 10.7150/jca.18731
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

The ABL Switch Control Inhibitor DCC-2036 Is Active Against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

Cancer Research
Cancer ResearchOncology
2011English

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Oncotarget
Oncology
2016English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

Oncotarget
Oncology
2018English

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Molecular Therapy - Nucleic Acids
Drug DiscoveryMolecular Medicine
2017English

Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Acute Myeloid Leukemia With BCR/ABL Fusion Chimera

Indian Journal of Hematology and Blood Transfusion
Hematology
2014English

Fluorescent In-Situ Hybridization (FISH) for BCR/ABL in Chronic Myeloid Leukemia After Bone Marrow Transplantation

Sao Paulo Medical Journal
Medicine
2001English

Re-Evaluating the Role of BCR/ABL in Chronic Myelogenous Leukemia

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy